FDA approves pembrolizumab regimens for muscle-invasive bladder cancer
FDA approval · scanx.trade · 2026-10-29. Number 3 in the UrologyWatch Top 5 for October 30, 2026.
The FDA approved pembrolizumab-based regimens for muscle-invasive bladder cancer, according to the report. Specific regimen details and trial data are not described in the brief item.
Why it matters: Expands the perioperative immunotherapy landscape in MIBC, an area with several recently reported but mixed trial results.
Source: scanx.trade
Loading today's edition…